Mind Medicine (MindMed), Inc. MNMD 深 沪
等待开盘 10-07 09:30:00 美东时间
15.02
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 15.02
- 总市值 114.28万
- 52周最高 15.29
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 4.70
- 委 比 0.00%
- 总股本 7.61万
- 历史最高 86.55
- 量 比 0
- 振 幅 0.00%
- 历史最低 2.20
- 每 手 1
- 风险率 0.87%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Optimi Health Completes Production Batch Of 5mg Naturally Derived Psilocybin Capsules, Manufactured End To End At cGMP Facility In Princeton, British Columbia
Optimi Health Corp. (NASDAQ:OPTH) (CSE:OPTI) (FSE: 8BN) ("Optimi" or the "Company"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion and quality release of a production batch of 5mg naturally derived psilocybin capsules, manufactu...
09-23 21:03
Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply
Optimi Health Corp. announced the completion of a cGMP batch of 5mg psilocybin capsules for its Phase 2 clinical trial evaluating psilocybin-assisted therapy for major depressive disorder (MDD) and commercial customers in Australia. The batch, manufactured under Health Canada's Drug Establishment Licence, will also supply licensed clinics in Australia where the capsules are prescribed for treatment-resistant depression. The trial, expected to enr...
09-23 13:00
巨头并购、政策开闸、数据井喷……迷幻药变天前夜，市场收到一记38亿美元的多头信号
上周四，礼来公司(LLY.US)宣布将以高达38亿美元的价格收购临床阶段迷幻药物制造商AtaiBeckley(ATAI.US)。这一动作标志着，大型制药企业正日...
07-20 08:48
Definium Therapeutics launches $500M public offering
Definium Therapeutics (DFTX) announced plans for an underwritten public offering of $500M of common shares and, for certain investors, pre-funded warrants. Definium also intends to grant underwriters ...
06-23 04:08
Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia
The Therapeutic Goods Administration (TGA) in Australia has updated its framework for psychedelic-assisted therapy (PAT), expanding therapist eligibility, allowing treatment in diverse settings, and enhancing scalability. Optimi Health Corp., a Canadian psychedelic pharmaceutical company, supplies MDMA for PTSD and psilocybin for treatment-resistant depression under the updated Authorized Prescriber (AP) scheme. Key changes include multidisciplin...
05-29 12:30
Mind Medicine Inc. Nears Pivotal DT120 Data
Mind Medicine Inc. (($DFTX)) has held its Q1 earnings call. Read on for the mai...
05-09 08:57
Definium Therapeutics Anxiety Drug A Multi-Billion Opportunity: Analyst
Stifel starts Definium coverage, citing strong DT120 potential in anxiety and key 2026 trial catalysts shaping outlook.
04-18 02:06
Psyence BioMed Expands Australian Clinical Network To 5 Sites For Psilocybin Phase IIb Trial
syence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the expansion
04-08 21:18
'Bipartisan Senators File Bill To Support Psychedelics Research And Treatment For Veterans' - Marijuana Moment
https://www.marijuanamoment.net/bipartisan-senators-file-bill-to-support-psychedelics-research-and-treatment-for-veterans/
03-28 01:28
